Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

DarioHealth Corp.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW CLIENTS SPAN MULTIPLE INDUSTRIES AND UNDERSCORE BROAD INCREASING DEMAND FOR DARIO'S MULTI-CONDITION DIGITAL HEALTH PLATFORM INNOVATIVE NEW PRICING MODEL IS HIGHLY ATTRACTIVE TO PROSPECTIVE CLIENTS  SUPPORTS DARIO'S CONTINUED MARKET MOMENTUM AND LEADING POSITION AS VALUE-BASED SOLUTION PROVIDER NEW YORK , OCT. 13, 2025 /PRNEWSWIRE/ --DARIOHEALTHCORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ANNOUNCED THE ADDITION OF SIX (6) NEW EMPLOYER CLIENTS TO ITS GROWING PORTFOLIO, UNDERSCORING ACCELERATING DEMAND FOR INTEGRATED, MULTI-CONDITION DIGITAL HEALTH SOLUTIONS THAT IMPROVE HEALTH AND REDUCE COSTS, AS WELL AS THE DEPLOYMENT OF A NEW PRICING MODEL THAT DEEPENS THE COMPANY'S VALUE-BASED CARE STRATEGY. THIS VALUE-BASED PRICING FRAMEWORK TIES PAYMENTS DIRECTLY TO MEMBER ENGAGEMENT AND CLINICAL PROGRESS  A STRUCTURE THAT AIMS TO HELP CLIENTS NAVIGATE COSTS BY LEVERAGINGDARIO'S INDUSTRY LEADING PLATFORM THAT DELIVERS 5X RETURN ON INVESTMENT ("ROI") AND APPROXIMATELY $5,000 ANNUAL SAVING PER DARIO USER.

DARIO SIGNS 6 NEW EMPLOYER CLIENTS REPRESENTING TENS OF THOUSANDS OF LIVES DEEPENING ITS LEADERSHIP IN VALUE-BASED CARE

COLLABORATION DESIGNED TO DRIVE MEASURABLE RETURN ON INVESTMENT ("ROI") FOR HEALTH PLANS BY REDUCING FALLS AND IMPROVING OUTCOMES FOR HIGH-RISK POPULATIONS, INCLUDING THOSE WITH OBESITY AND MEDICARE ADVANTAGE MEMBERS WITH FRAILTY AND BALANCE ISSUES GENERATING MORE THAN $50 BILLION ANNUALLY IN DIRECT MEDICAL COSTS, FALLS ARE ONE OF THE LEADING CAUSES OF INJURY AMONG OLDER ADULTS IN THE U.S. NEW YORK , OCT. 6, 2025 /PRNEWSWIRE/ --DARIOHEALTHCORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, AND ONESTEP, THE U.S. FOOD AND DRUG ADMINISTRATION ("FDA")-LISTED PLATFORM THAT DELIVERS CLINICAL-GRADE GAIT AND MOBILITY INSIGHTS USING ONLY A SMARTPHONE, TODAY ANNOUNCED A STRATEGIC COLLABORATION TO INTEGRATE ONESTEP'S CLINICAL-GRADE FALL RISK ASSESSMENT AND PREVENTION CAPABILITIES WITHIN DARIOHEALTH'S DIGITAL HEALTH SOLUTIONS ECOSYSTEM. THE PARTIES HAVE SIGNED A MEMORANDUM OF UNDERSTANDING ("MOU") AND EXPECT TO CONCLUDE A MASTER SERVICES AGREEMENT IN THE COMING WEEKS.

DARIOHEALTH AND ONESTEP ANNOUNCE STRATEGIC COLLABORATION TO INTEGRATE SMARTPHONE-ONLY, CLINICAL-GRADE FALL RISK ASSESSMENT TECHNOLOGY INTO DARIO'S DIGITAL HEALTH MULTI-CONDITION PLATFORM

BOARD FORMS SPECIAL COMMITTEE AND ENGAGES PERELLA WEINBERG PARTNERS AS FINANCIAL ADVISOR COMPANY COMPLETED AN OVERSUBSCRIBED $17.5 MILLION PRIVATE PLACEMENT TO CAPITALIZE ON SIGNIFICANT COMMERCIAL MOMENTUM DARIO OPTIMIZED ITS CAP TABLE BY CONVERTING PREFERRED SHARES INTO COMMON SHARES AND COMMON SHARES EQUIVALENTS, POSITIONING IT FOR FUTURE OPPORTUNITIES NEW YORK , SEPT. 25, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO)("DARIO" OR THE "COMPANY"), A LEADER IN DIGITAL HEALTH SOLUTIONS FOR CHRONIC CONDITION MANAGEMENT, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS INITIATED A COMPREHENSIVE STRATEGIC REVIEW TO MAXIMIZE SHAREHOLDER VALUE FOLLOWING MULTIPLE UNSOLICITED INBOUND STRATEGIC INQUIRIES FROM INTERESTED PARTIES.

DARIOHEALTH ANNOUNCES STRATEGIC REVIEW FOLLOWING MULTIPLE UNSOLICITED INBOUND EXPRESSIONS OF INTEREST

NEW YORK , SEPT. 22, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ANNOUNCED A PRIVATE PLACEMENT FOR THE PURCHASE AND SALE OF 2,713,180 SHARES OF COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) AT A PRICE OF $6.45 PER SHARE FOR EXPECTED AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $17.5 MILLION, BEFORE DEDUCTING OFFERING EXPENSES.

DARIOHEALTH ANNOUNCES $17.5 MILLION PRIVATE PLACEMENT OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES

NEW YORK , SEPT. 3, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP.(NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ISSUED A SHAREHOLDER UPDATE HIGHLIGHTING STRATEGIC PROGRESS, ROBUST MARKET TAILWINDS, AND ACCELERATING GROWTH OPPORTUNITIES.

DARIOHEALTH ISSUES SHAREHOLDER UPDATE: MULTI-CONDITION LEADERSHIP IN MOMENTUM DRIVEN DIGITAL HEALTH MARKET

NEW CUSTOMER LAUNCHES REPRESENTING 107,000 LIVES COVERED REINFORCE DARIO'S B2B2C MOMENTUM AND RECURRING REVENUE GROWTH DARIO'S MULTI-CONDITION DIGITAL HEALTH SOLUTIONS DELIVER REAL-TIME RESULTS FOR PREDIABETES, DIABETES, AND HYPERTENSION RESULTING IN A 23% REDUCTION IN HOSPITALIZATIONS, 9% REDUCTION IN HEALTHCARE UTILIZATION, AND $5,000 REDUCTION IN EMPLOYER COSTS PER USER 80% OF THE NEW ACCOUNTS SIGNED IN 2025 ARE FOR MULTI-CONDITION PROGRAMS PIPELINE OF COMMERCIAL OPPORTUNITIES INCREASES TO $67 MILLION NEW YORK , SEPT. 2, 2025 /PRNEWSWIRE/ --DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ANNOUNCED THE LAUNCH OF FIVE NEW CONTRACTS WITH SELF-INSURED EMPLOYERS.

DARIO SECURES FIVE NEW EMPLOYER CONTRACTS ACROSS CARDIOMETABOLIC SUITE INCLUDING ITS LARGEST EMPLOYER TO DATE, CONTRIBUTING TO ANNUAL RECURRING REVENUES BEGINNING Q3 2025

NEW YORK , AUG. 25, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ANNOUNCED THATA REVERSE STOCK SPLIT OF THE COMPANY'S ISSUED AND OUTSTANDING COMMON STOCK, PAR VALUE $0.0001 PER SHARE (THE "COMMON STOCK") AT A RATIO OF 20-FOR-1 IS EXPECTED TO BE IMPLEMENTED AT MARKET OPEN ON AUGUST 28, 2025. THE COMPANY'S COMMON STOCK WILL BEGIN TRADING ON THE NASDAQ CAPITAL MARKET ON A POST-SPLIT BASIS AT THE MARKET OPEN ONAUGUST 28, 2025, UNDER THE COMPANY'S EXISTING TRADING SYMBOL "DRIO", BUT WILL TRADE UNDER A NEW CUSIP NUMBER, 23725P 308.

DARIOHEALTH ANNOUNCES 20-TO-1 REVERSE STOCK SPLIT

SECOND QUARTER 2025 REVENUE WAS $5.4 MILLION, COMPARED TO $6.3 MILLION IN THE SECOND QUARTER OF 2024, AND $6.8 MILLION IN THE FIRST QUARTER OF 2025 - THE COMPANY BELIEVES THAT STRONG CLIENT MOMENTUM AND STRATEGIC WINS WILL OFFSET DECREASE IN REVENUES APPROXIMATELY $5 MILLION NEW COMMITTED ANNUAL RECURRING REVENUES ("CARR"); PLUS $53 MILLION PIPELINE OF COMMERCIAL OPPORTUNITIES, OVER $5 MILLION OF WHICH IS IN FINAL STAGES TOWARD CARR - ON TRACK TO SECURE TOTAL OF 40 NEW CLIENTS BY THE END OF 2025 TWO NEW HEALTH PLAN CLIENTS ARE EXPECTED TO REPRESENT MULTI-MILLION-DOLLAR OPPORTUNITIES FOR DARIO OVER TIME, INCLUDING A FULL-SUITE NATIONAL HEALTH PLAN SCHEDULED TO LAUNCH IN THE SECOND HALF OF 2025 GROSS MARGIN INCREASED TO 55% COMPARED TO 44% IN THE SECOND QUARTER OF 2024 THE CORE BUSINESS-TO-BUSINESS-TO-CONSUMER ("B2B2C") HAS BEEN OPERATING AT APPROXIMATELY 80% GROSS MARGINS ON A NON-GAAP BASIS SINCE THE FIRST QUARTER OF 2024 OPERATING LOSS IN THE SECOND QUARTER OF 2025 NARROWED BY 43% COMPARED TO THE SECOND QUARTER OF 2024 OPERATING EXPENSES FOR THE SECOND QUARTER OF 2025 DECREASED BY $6.8 MILLION, OR 36%, FROM THE SECOND QUARTER OF 2024 WITH ADDITIONAL EFFICIENCIES ANTICIPATED THROUGH ONGOING AI-DRIVEN PROCESS OPTIMIZATION DARIO WILL HOST AN INVESTOR CONFERENCE CALL AND WEBCAST AT 8:30 A.M. ET TODAY NEW YORK , AUG. 12, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, ALONG WITH STRATEGIC AND COMMERCIAL UPDATES.

DARIOHEALTH REPORTS SECOND QUARTER 2025 FINANCIAL AND OPERATING RESULTS

COMPANY TO HOST CONFERENCE CALL AND WEBCAST AT 8:30 A.M. EASTERN TIME NEW YORK , AUG. 5, 2025 /PRNEWSWIRE/ --DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, ANNOUNCED TODAY THAT IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE 2ND QUARTER ENDED JUNE 30 TH, 2025 AND WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:30 A.M.

DARIOHEALTH TO REPORT SECOND QUARTER 2025 RESULTS ON TUESDAY, AUGUST 12, 2025

DARIO AND GREENKEY JOIN FORCES TO TARGET $150 BILLION SLEEP APNEA MARKET, ADDRESSING 29 MILLION AMERICANS WITH UNMET NEEDS THROUGH INTEGRATED CHRONIC CARE SOLUTION NEW YORK AND SAN FRANCISCO , JUNE 26, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) ('DARIO' OR THE 'COMPANY'), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ANNOUNCED A STRATEGIC COMMERCIAL AGREEMENT WITH GREENKEY HEALTH ('GREENKEY'), AN INNOVATOR IN VALUE-BASED SLEEP HEALTH SOLUTIONS, TO BRING THE COMPREHENSIVE CARE PROGRAM TO PAYERS NATIONWIDE. THE COLLABORATION LEVERAGES THE STRENGTHS OF BOTH COMPANIES TO DELIVER A TIERED, DATA-DRIVEN SOLUTION FOR IMPROVING MEMBER HEALTH OUTCOMES, REDUCING HEALTHCARE COSTS, AND ENHANCING PRODUCTIVITY THROUGH THE INTEGRATION OF BEHAVIORAL HEALTH, SLEEP, AND CARDIOMETABOLIC CARE.

DARIO AND GREENKEY HEALTH ANNOUNCE STRATEGIC COMMERCIAL AGREEMENT TO TRANSFORM CHRONIC CONDITION MANAGEMENT AND SLEEP HEALTH FOR PAYERS NATIONWIDE

DARIO'S NEW RESEARCH SHOWS SUSTAINED OUTCOMES POST-GLP-1 FOR PLATFORM USERS AND 89% ACCURACY IN INNOVATIVE AI BLOOD GLUCOSE PREDICTION; THE COMPANY IS ACTIVELY WORKING TO LEVERAGE THESE FINDINGS IN COMMERCIAL DISCUSSIONS NEW YORK , JUNE 24, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ANNOUNCED FOUR NEW STUDIES PRESENTED THIS PAST WEEKEND AT THE 85TH ANNUAL AMERICAN DIABETES ASSOCIATION ("ADA") SCIENTIFIC SESSIONS IN CHICAGO. THE RESEARCH, WHICH REPRESENTS DARIO'S 25TH PUBLISHED STUDY AT THE ADA'S SCIENTIFIC SESSIONS OVER THE LAST DECADE, INCLUDES GROUNDBREAKING FINDINGS IN SUSTAINING GLP-1 WEIGHT LOSS AND ARTIFICIAL INTELLIGENCE ("AI")-POWERED PERSONALIZATION THAT HIGHLIGHT THE COMPANY'S PLATFORM'S CRITICAL CONTRIBUTION IN THE DIGITAL HEALTH MARKET.

DarioHealth Corp.

DRIO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DarioHealth Corp.

DRIO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DRIO